| Assessment Status | Rapid Review Complete |
| HTA ID | 25065 |
| Drug | Obinutuzumab |
| Brand | Gazyvaro® |
| Indication | Obinutuzumab (Gazyvaro®) in combination with mycophenolate mofetil, is indicated for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis. |
| Assessment Process | |
| Rapid review commissioned | 04/11/2025 |
| Rapid review completed | 08/12/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that obinutuzumab not be considered for reimbursement for this indication at the submitted price. |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here